A Rapid Quantitative Saliva THC Sensor Was Not an Impairment Breathalyzer
A rapid oral-fluid THC assay demonstrated sensitive chemical measurement in a proof-of-concept study. Its analytical performance did not establish a concentration threshold that diagnoses driving impairment.
What the device measured
The EPOCH system combined oral-fluid processing, a membrane-based competitive immunoassay and smartphone-assisted optical measurement. Higher THC concentrations changed antibody capture and light transmission, allowing quantitative estimation rather than a simple positive–negative strip result.
The reported analytical detection limit was 0.17 ng/mL, with the sample-to-result process completed within minutes. A detection limit is an instrument-performance characteristic, not the point at which a person becomes impaired.
Promising samples were not a roadside population
The demonstration compared oral fluid from 43 cannabis users with 43 controls and included longitudinal observations after use. It showed that the device could detect and follow oral THC in these selected specimens.
A selected user–control comparison does not reproduce all conditions encountered at roadside, including uncertain last use, mixed products, co-exposures and concentrations near a decision cutoff. Repeated samples from the same person also cannot be counted as independent validation participants.
Chemical specificity and functional validity remain separate
The authors described future work involving larger longitudinal cohorts and potentially adding cognitive assessments. That distinction matters: a molecular sensor does not become a functional test merely because it is fast, portable or quantitative.
Oral-fluid THC can also reflect deposition in the mouth, so its decline is not interchangeable with a blood or brain elimination curve. The study supports further analytical development and field validation, while leaving individual impairment classification and real-world diagnostic performance as separate questions.
Related: THC concentration and impairment.
Primary research
A rapid assay provides on-site quantification of tetrahydrocannabinol in oral fluid. Science translational medicine (2021).
